Company profile
GRAIL Inc.
NASDAQ: GRAL · Healthcare · Biotechnology
#312 of 1,418 Healthcare companies by revenue63rd-percentile growth
EA Score
51DFH 62DQ 23GM 71SS 61
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$156.1M
Rev growth YoY (TTM)
+19.4%
Net income (FY)
-$408.4M
Employees
910
as of 2026-08-08
Market cap
$3.0B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$147.2M$147.2M2025
Net income-$408.4M-$408.4M2025
Operating income-$562.2M-$562.2M2025
Total assets$2.9B$2.9B2025
Liabilities$344.2M$344.2M2025
Equity$2.6B$2.6B2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY25
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is GRAIL Inc.’s revenue?
GRAIL Inc. booked $147.2M in FY2025 revenue, growing 17% year over year — faster than most Healthcare companies we track, at a -277.5% net margin.
Peers · Healthcare
MacroGenics, Inc.54DNeuronetics, Inc.59CElite Pharmaceuticals, Inc.77B+Cronos Group Inc.69BKaryopharm Therapeutics Inc.49DiAnthus Capital Holdings, Inc.46DNeighbors
San Mateo →Key facts
CEOJoshua J. Ofman
SectorHealthcare
IndustryBiotechnology
HeadquartersMenlo Park, CA
ExchangeNASDAQ: GRAL
Employees910
IPO date2024-06-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.